BF BFLY Butterfly Network, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Reports Butterflies selected to participate in Sam Altman's BCI venture; observational note, no position or price view stated.

Author highlights these names on their focus list as showing strength and being under-owned.

"Speaker lists six names as objectively strong focus-list candidates; no position language, catalyst, or per-name reasoning provided."

The author highlights a broad basket of interesting names across Physical AI, NAND, and other sectors without stating any explicit positions or directional calls, so all tickers are indexed as watch.

The author is compiling a research thread of user-recommended non-AI tickers, listing them as a factual watchlist

Included in a swing trading focus list, no specific directional catalyst provided.

Author highlights multiple chart standouts and swing candidates but explicitly says no moves are being made, so all tickers are watch-only despite bullish chart commentary.

Author flags BFLY as a potential swing entry based on chart setup; no position taken, no specific catalyst cited.

Notes a fantastic chart setup and is eyeing the stock for a potential swing entry.

Author highlights a basket of names showing relative strength that he brought higher on his focus list, but this is a momentum watchlist rather than an explicit position or forward call.

Author lists names showing relative strength that moved higher on their focus list, a watchlist update without explicit position language or forward call.

Butterfly Network has promising handheld ultrasound/MRI technology, fell from $20 to $8, can be bought a little lower as a speculative position with no major flaws.

Butterfly Network's ultrasound chips are explicitly named as the sensor technology powering Midjourney's 500,000-emitter full-body scanner. This validates their chip technology for a high-volume, non-diagnostic medical application and could open a new revenue stream if Midjourney scales to 50,000 scanners by 2031. Risk: Midjourney's scanner is still a prototype; FDA approval path is narrow and long. BFLY's revenue concentration risk if Midjourney is the sole customer for this application.

Butterfly Network (BFLY) builds the ultrasound-on-chip technology that packs thousands of transducer elements into a single semiconductor die. Midjourney just launched a full-body medical scanner and is licensing Butterfly's technology and buying its chips. The deal gives Butterfly three revenue streams: a fixed license ($15M upfront plus $10M/year over 5 years), chip sales (the real volume lever—each scanner uses a dense multi-row ring of chips, potentially 15-50 thousand in silicon per unit), and a revenue share tied to hardware. Revenue would land about 10-70% above today's level. The stock pumped 56% on the announcement.

Midjourney Medical's full-body ultrasound scanner is partnered with Butterfly Network, a public company; the stock is up almost 50% on the news, and the deal combines Midjourney/David Holz's vision with Butterfly's long-developed ultrasound technology.

The author notes that Butterfly Network's 10x daily volume is unusual but does not state a personal position or forward call, so it is indexed as a watch.

Buy BFLY as the underlying hardware supplier to Midjourney's body scanner: 40 Ultrasound-on-Chip modules per unit, a $74M licensing deal over five years, and Midjourney targeting 50,000 scanners with per-unit royalties accruing to BFLY at scale.

Author highlights $BFLY in context of Midjourney's full-body ultrasound scanner announcement, which leverages Butterfly's ultrasound-on-chip platform via a licensing deal disclosed November 2025 worth up to $74M; management presented at TD Cowen conference same day.

Corrects previous analysis to note that Butterfly Network has an agreement for a share of revenues.

Analyzes Butterfly Network's Midjourney deal, noting that the revenue impact is capped and the stock's valuation is already high.